US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Clinical Trials ETF

43.29

+0.03220.07%

Post-market: 43.290.00000.00%16:15 EDT

Volume:17.37K

Turnover:755.83K

Market Cap:41.12M

PE:- -

High:44.03

Open:42.82

Low:42.82

Close:43.26

52wk High:56.18

52wk Low:27.62

Shares:950.00K

Float Shares:950.00K

Volume Ratio:0.86

T/O Rate:1.83%

Dividend:0.65

Dividend Rate:1.51%

ROE:--

ROA:--

PB:0.93

PE(LYR):- -

Loading ...

Overview Company News Filings

Viking Therapeutics Advances VK2735 Obesity Trial, Keeping VKTX in the Weight Loss Race

Psychedelic: Optimi completes psilocybin production for Phase 2 trial

BeOne Medicines Advances Phase 3 Liver Cancer Trial With BGB-B2033

AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104

Sanofi’s Chinese Pediatric Meningococcal Vaccine Trial Advances, Sharpening Long-Term Growth Prospects for SNY

Adagene Wins NMPA IND Clearance for Novel HER2xCD3 T-Cell Engager ADG138

Avalyn Pharma announces published results from Phase 1 trials of AP02

Tiziana Life Sciences Completes Last Patient Visit in Phase 2a INFORM-MS Trial

Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint

US Claims Permanent Control While Denmark Rejects Sovereignty Transfer: Who Truly Benefits from the Greenland Deal?

Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference

Shionogi’s Phase 3 COVID-19 Antiviral Trial Puts SGIOF Back in the Spotlight

TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset

Mattel Enters Licensing Deal With BBC Studios Over Bluey Series Collection

MT Newswires Live

Mattel, BBC Studios announce multi-brand global licensing partnership for Bluey

10 Tuesday AM Reads

The Big Picture

SillaJen seeks approval for Phase 1 trial of Dexibuprofen injection

Syntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline

AdAlta takes ‘East to West’ CAR-T strategy and EW-001 data to U.S. investors

Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/BBC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BBC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Clinical Trials ETF","latestPrice":43.2874,"timestamp":1791403200000,"preClose":43.2552,"halted":0,"volume":17369,"hourTrading":{"tag":"盘后","latestPrice":43.2874,"preClose":43.2874,"latestTime":"16:15 EDT","volume":12,"amount":519.426636,"timestamp":1791404100369,"change":0,"changeRate":0,"amplitude":0.000171},"delay":0,"changeRate":0.000744419168099928,"floatShares":950000,"shares":950000,"eps":0,"marketStatus":"Post-Mkt","change":0.0322,"latestTime":"10-07 19:04:16 EDT","open":42.82,"high":44.03,"low":42.82,"amount":755831,"amplitude":0.027974,"askPrice":51.01,"askSize":100,"bidPrice":29.64,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791417600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":43.2552,"sharesOutstanding":900004,"nav":44.728,"aum":42491680.3,"dividendRate":0.01509,"bidAskSpread":0.002127,"postHourTrading":{"tag":"盘后","latestPrice":43.2874,"preClose":43.2874,"latestTime":"16:15 EDT","volume":12,"amount":519.426636,"timestamp":1791404100369,"change":0,"changeRate":0,"amplitude":0.000171},"volumeRatio":0.863082,"impliedVol":0.371,"impliedVolPercentile":0.8207},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBC\",,,,,undefined,":{"symbol":"BBC","floatShares":950000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.863082,"shares":950000,"dividePrice":0.6532,"high":44.03,"amplitude":0.027974,"preClose":43.2552,"low":42.82,"week52Low":27.62,"pbRate":"0.93","week52High":56.18,"institutionHeld":0,"latestPrice":43.2874,"eps":0,"divideRate":0.01509,"volume":17369,"delay":0,"ttmEps":0,"open":42.82,"prevYearClose":38.56,"prevWeekClose":44.5638,"prevMonthClose":46.2948,"prevQuarterClose":46.2948,"fiveDayClose":46.2948,"twentyDayClose":51.51,"sixtyDayClose":51.5732},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBC\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"BBC","amount":0.65544,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2024-12-20","symbol":"BBC","amount":0.23947,"announcedDate":"2024-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-20","defaultRemindTime":1734705000000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-20","currency":"USD","dateTimestamp":1734670800000,"payDate":"2024-12-27"},{"date":"2023-12-20","symbol":"BBC","amount":0.0823,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"Virtus LifeSci Biotech Clinical Trials ETF","recordDate":"2023-12-29","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBC\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-29","value":0.0823,"currency":"USD"},{"executeDate":"2024-12-20","recordDate":"2024-12-20","paymentDate":"2024-12-27","value":0.23947,"currency":"USD"},{"executeDate":"2025-12-22","recordDate":"2025-12-22","paymentDate":"2025-12-29","value":0.65544,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2670492925","title":"Viking Therapeutics Advances VK2735 Obesity Trial, Keeping VKTX in the Weight Loss Race","url":"https://stock-news.laohu8.com/highlight/detail?id=2670492925","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670492925?lang=en_us&edition=fundamental","pubTime":"2026-09-25 00:31","pubTimestamp":1790267475,"startTime":"0","endTime":"0","summary":"Viking Therapeutics ($VKTX) announced an update on their ongoing clinical study. Viking Therapeutics, Inc. is running a Phase 1 trial called “A Pha...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/viking-therapeutics-advances-vk2735-obesity-trial-keeping-vktx-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/viking-therapeutics-advances-vk2735-obesity-trial-keeping-vktx-in-the-weight-loss-race?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","OZEM","BK4585","VKTX","THNR","BK4599","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669449944","title":"Psychedelic: Optimi completes psilocybin production for Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669449944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669449944?lang=en_us&edition=fundamental","pubTime":"2026-09-24 22:30","pubTimestamp":1790260228,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a production completion, a strate...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-optimi-completes-psilocybin-production-for-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-optimi-completes-psilocybin-production-for-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669480110","title":"BeOne Medicines Advances Phase 3 Liver Cancer Trial With BGB-B2033","url":"https://stock-news.laohu8.com/highlight/detail?id=2669480110","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669480110?lang=en_us&edition=fundamental","pubTime":"2026-09-24 00:31","pubTimestamp":1790181069,"startTime":"0","endTime":"0","summary":"BeOne Medicines ($ONC) announced an update on their ongoing clinical study. BeOne Medicines has launched a Phase 3 trial titled “A Randomized, Open...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-phase-3-liver-cancer-trial-with-bgb-b2033?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beone-medicines-advances-phase-3-liver-cancer-trial-with-bgb-b2033?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BGB","MDCO","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669488235","title":"AC Immune Posts Strong Week-100 Phase 2 Data for Parkinson’s Vaccine ACI-7104","url":"https://stock-news.laohu8.com/highlight/detail?id=2669488235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669488235?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:28","pubTimestamp":1790162930,"startTime":"0","endTime":"0","summary":"AC Immune SA ( ($ACIU) ) has shared an announcement. On September 23, 2026, AC Immune reported that Part 1 of its VacSYn Phase 2 trial of ACI-7104 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ac-immune-posts-strong-week-100-phase-2-data-for-parkinsons-vaccine-aci-7104?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ac-immune-posts-strong-week-100-phase-2-data-for-parkinsons-vaccine-aci-7104?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","BK4113","ACI","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669126381","title":"Sanofi’s Chinese Pediatric Meningococcal Vaccine Trial Advances, Sharpening Long-Term Growth Prospects for SNY","url":"https://stock-news.laohu8.com/highlight/detail?id=2669126381","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669126381?lang=en_us&edition=fundamental","pubTime":"2026-09-23 00:30","pubTimestamp":1790094635,"startTime":"0","endTime":"0","summary":"Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi (SNY) is running a Phase 3 trial in China to test an investigational f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofis-chinese-pediatric-meningococcal-vaccine-trial-advances-sharpening-long-term-growth-prospects-for-sny?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sanofis-chinese-pediatric-meningococcal-vaccine-trial-advances-sharpening-long-term-growth-prospects-for-sny?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","BBC","BK4007","PSIL","IE00BFXG1179.USD","SNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144262","title":"Adagene Wins NMPA IND Clearance for Novel HER2xCD3 T-Cell Engager ADG138","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144262","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144262?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:27","pubTimestamp":1790080070,"startTime":"0","endTime":"0","summary":"Adagene ( ($ADAG) ) has issued an announcement. Adagene Inc., a platform-driven, clinical-stage biotechnology company listed on Nasdaq, specializes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adagene-wins-nmpa-ind-clearance-for-novel-her2xcd3-t-cell-engager-adg138?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adagene-wins-nmpa-ind-clearance-for-novel-her2xcd3-t-cell-engager-adg138?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","LNGR","IBB","IEIH","BK4139","BBC","AGNG","SYNB","RSPH","FWD","FHLC","XT","ADAG","JDOC","LCLG","BK4588","BBP","DARP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669661341","title":"Avalyn Pharma announces published results from Phase 1 trials of AP02","url":"https://stock-news.laohu8.com/highlight/detail?id=2669661341","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669661341?lang=en_us&edition=fundamental","pubTime":"2026-09-21 21:10","pubTimestamp":1789996248,"startTime":"0","endTime":"0","summary":"Avalyn Pharma (AVLN) announced that Respiratory Research has published detailed results from two Phase 1 clinical trials of AP02 in healthy volunte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/avalyn-pharma-announces-published-results-from-phase-1-trials-of-ap02-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","IDNA","BMED","NVIB","GDOC","MEDX","BK4007","AVLN","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669684681","title":"Tiziana Life Sciences Completes Last Patient Visit in Phase 2a INFORM-MS Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669684681","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669684681?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:27","pubTimestamp":1789990051,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences ( ($TLSA) ) has shared an announcement. Tiziana Life Sciences Ltd, a clinical-stage biotechnology company specializing in imm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-completes-last-patient-visit-in-phase-2a-inform-ms-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-completes-last-patient-visit-in-phase-2a-inform-ms-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RSPH","BBP","FWD","IEIH","AGNG","BK4585","JDOC","FHLC","XT","DARP","BBC","IBB","LNGR","SYNB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668318487","title":"Cue Biopharma announces Phase 2 trial of CUE-221 met primary endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2668318487","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668318487?lang=en_us&edition=fundamental","pubTime":"2026-09-20 22:15","pubTimestamp":1789913705,"startTime":"0","endTime":"0","summary":"Cue Biopharma (CUE) announced positive topline results from the Phase 2 clinical trial of CUE-221 conducted in China by Genesis Life Sciences, a re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cue-biopharma-announces-phase-2-trial-of-cue-221-met-primary-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","HYLG","IDNA","PSIL","CUE","NVIB","BBC","BK4139","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148504480","title":"US Claims Permanent Control While Denmark Rejects Sovereignty Transfer: Who Truly Benefits from the Greenland Deal?","url":"https://stock-news.laohu8.com/highlight/detail?id=1148504480","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148504480?lang=en_us&edition=fundamental","pubTime":"2026-09-20 07:30","pubTimestamp":1789860634,"startTime":"0","endTime":"0","summary":"The United States, Denmark, and Greenland's government announced on the 18th that they had reached an agreement concerning Greenland's security, although the deal's text has yet to be released....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668180509","title":"Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2668180509","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668180509?lang=en_us&edition=fundamental","pubTime":"2026-09-18 07:48","pubTimestamp":1789688927,"startTime":"0","endTime":"0","summary":"Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics, a clinical-stage biotechnology company, develops disease-modifying...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-asx-smidcaps-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-to-spotlight-msa-program-at-asx-smidcaps-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","LNGR","BK4539","BBC","BBP","LENZ","JDOC","BK4007","FHLC","BK4585","BK4139","XT","AGNG","RSPH","DARP","FWD","BK4588","IEIH","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668999316","title":"Shionogi’s Phase 3 COVID-19 Antiviral Trial Puts SGIOF Back in the Spotlight","url":"https://stock-news.laohu8.com/highlight/detail?id=2668999316","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668999316?lang=en_us&edition=fundamental","pubTime":"2026-09-18 00:30","pubTimestamp":1789662653,"startTime":"0","endTime":"0","summary":"Shionogi & Co ($SGIOF) announced an update on their ongoing clinical study. Shionogi & Co. (SGIOF) is running a Phase 3 trial called “A Study of Se...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/shionogis-phase-3-covid-19-antiviral-trial-puts-sgiof-back-in-the-spotlight?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/shionogis-phase-3-covid-19-antiviral-trial-puts-sgiof-back-in-the-spotlight?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BNTX","SGIOF","PSIL","BK4568","BK4551","BK4548","BK4139","BK4535","BK4588","BK4007","BBC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667089246","title":"TME Pharma CEO Emphasizes Cash Discipline and Strategic Partnering for Lead Cancer Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2667089246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667089246?lang=en_us&edition=fundamental","pubTime":"2026-09-16 14:37","pubTimestamp":1789540665,"startTime":"0","endTime":"0","summary":"TME Pharma N.V. ( ($FR:ALTME) ) has provided an announcement. TME Pharma, a clinical-stage biotech group developing therapies for brain cancer and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tme-pharma-ceo-emphasizes-cash-discipline-and-strategic-partnering-for-lead-cancer-asset?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tme-pharma-ceo-emphasizes-cash-discipline-and-strategic-partnering-for-lead-cancer-asset?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","BK4563","DBB","BK4552","TME","LU0828238088.HKD","BK4509","LU0509642566.USD","LU0359201612.USD","LU0359202008.SGD","LU0456842615.SGD","NVIB","01698","LU0269904917.USD","BK4108","BK4548","LU1023057109.AUD","IE00BYTNYN87.SGD","XBIX","SG9999011746.SGD","BK4531","IE00B12V2V27.USD","BK4535","IE00BYQNZ168.SGD","BK4565","BK4526","BK4571","LU2039709279.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667261656","title":"Mattel Enters Licensing Deal With BBC Studios Over Bluey Series Collection","url":"https://stock-news.laohu8.com/highlight/detail?id=2667261656","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667261656?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:27","pubTimestamp":1789489632,"startTime":"0","endTime":"0","summary":"Mattel  said Tuesday it entered a multi-year licensing deal with BBC Studios to bring the Bluey animation series through products from five of its franchises, starting this fall.The collection will feature characters from Bluey across Little People figures, Barbie accessories, Polly Pocket playsets, Hot Wheels vehicles, and UNO card games, according to a statement.Price: 13.54, Change: -0.49, Percent Change: -3.49","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BBC","BK7104","BK7507","MAT","BK4190","BK7506","MAT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667626951","title":"Mattel, BBC Studios announce multi-brand global licensing partnership for Bluey","url":"https://stock-news.laohu8.com/highlight/detail?id=2667626951","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667626951?lang=en_us&edition=fundamental","pubTime":"2026-09-16 00:05","pubTimestamp":1789488312,"startTime":"0","endTime":"0","summary":"Mattel (MAT) and BBC Studios announced a multi-year global licensing partnership that will bring Bluey to five of Mattel’s franchises. “Fans around...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mattel-bbc-studios-announce-multi-brand-global-licensing-partnership-for-bluey-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mattel-bbc-studios-announce-multi-brand-global-licensing-partnership-for-bluey-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","BK4190","MAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667662442","title":"10 Tuesday AM Reads","url":"https://stock-news.laohu8.com/highlight/detail?id=2667662442","media":"The Big Picture","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667662442?lang=en_us&edition=fundamental","pubTime":"2026-09-15 18:30","pubTimestamp":1789468243,"startTime":"0","endTime":"0","summary":"What if Elon Musk Was Always Elon Musk?The most disturbing part of the controversial new four-hour documentary. . Why So Many AI Researchers Think the Machines Could Kill Everyone: A combination of rapid advances, recursive self-improvement, and agentic swarms are genuinely “spooking people” inside big labs. Will Knight on Rishub Jain, who left Google DeepMind after realizing that using AI to build the next generation of AI was removing humans from the equation. see alsoAI Is Powerful Enough to Crack Our Hardest Math Problems — and Kill Us All: An Anthropic safety researcher puts the odds of annihilation above 10% — doomsday now more likely than Steph Curry missing a free throw. . ‘Offensively Cheap’: Solar Power Is Looking Up: Rachel Millard reports from Chakwal, Pakistan, where a cement maker is turning dry earth and peach groves into a forest of panels — solar already generates over a quarter of its power. . Video of the day: China Found Something Better Than Oil","market":"nz","thumbnail":"https://ritholtz.com/wp-content/uploads/2030/07/headcount.png","type":0,"news_type":0,"thumbnails":["https://ritholtz.com/wp-content/uploads/2030/07/headcount.png"],"rights":{"source":"ritholtz_highlight","url":"https://ritholtz.com/2026/09/10-tuesday-am-reads-490/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://ritholtz.com/2026/09/10-tuesday-am-reads-490/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"ritholtz_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667261990","title":"SillaJen seeks approval for Phase 1 trial of Dexibuprofen injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2667261990","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667261990?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:46","pubTimestamp":1789451195,"startTime":"0","endTime":"0","summary":"SillaJen, Inc. ( ($KR:215600) ) has provided an announcement. SillaJen, Inc. has applied to Korea’s Ministry of Food and Drug Safety for approval t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sillajen-seeks-approval-for-phase-1-trial-of-dexibuprofen-injection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sillajen-seeks-approval-for-phase-1-trial-of-dexibuprofen-injection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667694618","title":"Syntara Sets 2026 AGM Date as It Refocuses on Fibrosis and Cancer Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2667694618","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667694618?lang=en_us&edition=fundamental","pubTime":"2026-09-15 08:16","pubTimestamp":1789431375,"startTime":"0","endTime":"0","summary":"Syntara Limited ( ($AU:SNT) ) has provided an update. Syntara Limited, an ASX-listed clinical-stage biotechnology company based in Sydney, develops...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/syntara-sets-2026-agm-date-as-it-refocuses-on-fibrosis-and-cancer-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/syntara-sets-2026-agm-date-as-it-refocuses-on-fibrosis-and-cancer-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DARP","BK4585","FWD","BK4588","BBC","XT","LNGR","JDOC","SYNB","IEIH","FHLC","RSPH","IBB","BBP","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691804","title":"AdAlta takes ‘East to West’ CAR-T strategy and EW-001 data to U.S. investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691804?lang=en_us&edition=fundamental","pubTime":"2026-09-15 07:16","pubTimestamp":1789427795,"startTime":"0","endTime":"0","summary":"The latest update is out from AdAlta Ltd. ( ($AU:1AD) ). AdAlta Limited, an Australian clinical-stage biotech specialising in cellular immunotherap...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adalta-takes-east-to-west-car-t-strategy-and-ew-001-data-to-u-s-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adalta-takes-east-to-west-car-t-strategy-and-ew-001-data-to-u-s-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","BBC","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667576635","title":"Entropy Neurodynamics Reports Durable 12-Week Gains in BED Trial of Psychedelic Therapy TRP-8803","url":"https://stock-news.laohu8.com/highlight/detail?id=2667576635","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667576635?lang=en_us&edition=fundamental","pubTime":"2026-09-14 07:19","pubTimestamp":1789341541,"startTime":"0","endTime":"0","summary":"Tryptamine Therapeutics ( ($AU:ENP) ) has shared an update. Entropy Neurodynamics Limited, a clinical-stage biotech in Melbourne, is developing pre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/entropy-neurodynamics-reports-durable-12-week-gains-in-bed-trial-of-psychedelic-therapy-trp-8803?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","IE00BMG7P926.USD","IE000HOSIQF4.USD","TPYP","IE00BD4GTW91.USD","IE00BD4GTV84.USD","TRP","MLPX","IE00BMG7P587.USD","IE00BMG7P819.SGD","BBC","IE00BMG7P694.USD","IE00BD4GTT62.SGD","IE000SL1IH01.SGD","BK4144","EINC","NVIB","XBIX","IE000WXP2NQ0.USD","IE00BMG7P702.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":2,"totalSize":168,"code":"91000000","status":"200"}]}}